Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to NL6902213ApriorityCriticalpatent/NL6902213A/en
Publication of NL6902213ApublicationCriticalpatent/NL6902213A/en
Cpds. of formula (I) R' = OH opt. esterified or etherified Y = H, OH opt. esterified. Thymolytic, suprarenal inhibitory and anti-inflammatory activity. 0.3-3 mg/kg. orally or 1-10 mg/kg. s.c. in rats markedly inhibits foreign-body-induced granuloma. The thymolytic effect is 10 times greater than the anti-inflammatory effect when a 21-acetate is admin. orally. The 21-pivalate corresponding to the 21-acetate has a similar anti-inflammatory activity but the thymolytic activity is less than the anti-inflamm. activity. May be used in animal foods.